Supplementary Figure 8 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors

Kyle Brandon Williams; Alex T. Larsson; Bryant J. Keller; Katherine E. Chaney; Rory L. Williams; Minu M. Bhunia; Garrett M. Draper; Tyler A. Jubenville; Wendy A. Hudson; Gunda I. Georg; Christopher L. Moertel; Nancy Ratner; David A. Largaespada

doi:10.1158/1535-7163.31248656

Supplementary Figure 8 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors

2026 Open access

Read full text

Authors: Kyle Brandon Williams, Alex T. Larsson, Bryant J. Keller, Katherine E. Chaney, Rory L. Williams, Minu M. Bhunia, Garrett M. Draper, Tyler A. Jubenville, Wendy A. Hudson, Gunda I. Georg, Christopher L. Moertel, Nancy Ratner

+1 more

David A. Largaespada

DOI: 10.1158/1535-7163.31248656

Cited by: 0

Abstract

Supplementary Figure 8 shows the pathway enrichment in transcriptome data for MPNST cells treated with selumetinib, rigosertib, or the combination.

Fields of Study & Subjects

Neurofibromatosis and Schwannoma Cases Protein Tyrosine Phosphatases Neuroblastoma Research and Treatments

Publication details

Publication date: 4 February 2026